Chinese and American scientists have jointly developed a new antibody targeting the Middle East Respiratory Syndrome (MERS) virus, which has claimed the lives of 16 people and infected 150 others in the recent outbreak in South Korea.
Shanghai's Fudan University, which worked with US National Institutes of Health to develop the antibody, on Monday said tests on animals have seen "very effective" results, Xinhua news agency reported.
Jiang Shibo, who led the research team at Fudan, said the m336 antibody could neutralise MERS virus more effectively than other antibodies.
Zhong Nanshan, a renowned respiratory expert, called for an immediate clinical trial.
The m336 antibody treatment has proved more effective when coupled with a specific type of polypeptide, Jiang added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app